share_log

Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate

Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate

regulus therapeutics第二季度每股收益为$(0.17),低于$(0.13)的预期。
Benzinga ·  08/09 05:34

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 54.05 percent increase over losses of $(0.37) per share from the same period last year.

Regulus Therapeutics(纳斯达克:RGLS)报告每股亏损$(0.17),比分析师共识预期的$(0.13)低了30.77%。这是与去年同期每股亏损$(0.37)相比增加了54.05%。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发